Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03453060 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability Study of E-WE Thrombin in Healthy Adult Subjects
A Phase 1 study of Thrombosis, sponsored by Aronora.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT03453060 is a Phase 1 study of Thrombosis that has completed, run by Aronora. The registered enrollment target is 21 participants, below the 470-participant average among 28 other Thrombosis trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03453060, a Phase 1 study of Thrombosis, has completed, sponsored by Aronora.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess the safety, tolerability and pharmacodynamics of a single iv dose of E-WE Thrombin in healthy adult subjects.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG E-WE Thrombin- Dose 1
- DRUG E-WE Thrombin- Dose 2
- DRUG E-WE Thrombin- Dose 3
- DRUG E-WE Thrombin- Dose 4
Study Locations (1)
Arizona
- Celerion - Tempe
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2018-05-30 |
| Est. Completion | 2018-11-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03453060
The ClinicalTrials.gov registry entry for NCT03453060 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 470-participant average among 28 other Thrombosis trials with a reported enrollment target (96% lower). The listed sponsor is Aronora, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Thrombosis appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.
NCT03453060 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.
Frequently Asked Questions
What is clinical trial NCT03453060 about?
NCT03453060 is a clinical study titled "Safety and Tolerability Study of E-WE Thrombin in Healthy Adult Subjects". The purpose of this study is to assess the safety, tolerability and pharmacodynamics of a single iv dose of E-WE Thrombin in healthy adult subjects.
What is the current status of trial NCT03453060?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2018-05-30. Estimated completion is 2018-11-25.
What conditions does trial NCT03453060 study?
This clinical trial studies the following conditions: Thrombosis.
What interventions are being tested in trial NCT03453060?
The interventions under investigation include: Placebo (OTHER), E-WE Thrombin- Dose 1 (DRUG), E-WE Thrombin- Dose 2 (DRUG), E-WE Thrombin- Dose 3 (DRUG), E-WE Thrombin- Dose 4 (DRUG).
Who is sponsoring clinical trial NCT03453060?
This trial is sponsored by Aronora, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03453060 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thrombosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Positron Emission Tomography (PET) Imaging of Thrombosis
RECRUITING · Phase 1
-
Bioavailability Study Comparing Modified Release To Immediate Release Apixaban Tablets In Healthy Volunteers
COMPLETED · Phase 1
-
Pharmacokinetic and Metabolism of [14^C] BMS-986177 in Healthy Male Participants
COMPLETED · Phase 1
-
Reversibility of Apixaban Anticoagulation With the Four Factor Prothrombin Complex Concentrate Kcentra
COMPLETED · Phase 1
-
A Study to Evaluate the Safety and Pharmacokinetics of BMS-986177 in Participants With End-stage Renal Dysfunction on Chronic Stable Hemodialysis Treatment
COMPLETED · Phase 1
-
Evaluate Pharmacokinetics and Safety of BMS-986177 in Participants With Normal Renal Function and With Moderate or Severe Renal Impairment
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.